At Sterling IRB, we have a custom approach proven to effectively partner with institutions. We know institutions working on critical gene therapy and oncology therapies need an experienced partner and review board, as well as a comprehensive solution that includes IBC services. Where investigators know urgency is certain, flexibility is essential, and response time is immediate.
Sterling IRB is a participating member of SMART IRB. Through a flexible master IRB reliance agreement, standard operating procedures, and complementary tools and resources, SMART IRB is designed to harmonize and streamline the IRB review process for multisite studies, while ensuring a high level of protection for research participants.
As an independent review board, Sterling IRB is able to serve as the IRB of record for institutions such as medical centers, academic institutions, and community hospitals if one of the following conditions is met:
- There is no local IRB with jurisdiction.
- The local IRB has jurisdiction, but defers it to Sterling IRB in writing.
Institutions who are requesting that Sterling serve as the IRB of record for a study that would normally fall under local IRB jurisdiction may submit the IRB Jurisdiction Form located in the Forms for Institutions section of the Forms page.
If an institution is conducting research under Federalwide Assurance (FWA) and plans to use the services of Sterling IRB, it must complete an IRB Authorization Agreement (available within the Forms for Institutions section of the Forms page), and may need to update its FWA if Sterling is not already included as a designated IRB. Please note that Sterling IRB does not require additional reliance/authorization agreements from participating SMART IRB institutions.
Investigators who conduct research at institutions and are submitting an application to Sterling should be aware of any obligations that they may have to use the institution’s IRB.